ArticleTransfusion2020
Blood transfusion safety in the country of Georgia: collateral benefit from a national hepatitis C elimination program.
Article in Transfusion, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 14 citations in OpenAlex.
- [Screening of Hepatitis C virus in blood donors over 11 years].Revista medica del Instituto Mexicano del Seguro Social · 2026Observational
- Transfusion-transmitted malaria in India: A national survey of epidemiology and testing practices.Vox sanguinis · 2026Article
- Prevalence of transfusion transmitted infections by mode of donation and remuneration status among blood donors in Georgia, 2018-2023.Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis · 2025Article
- Evaluation of Hepatitis C Virus Transmission Through Endoscopy Procedures in the Country of Georgia.Journal of viral hepatitis · 2025Article
- Trends in new hepatitis C virus infections among repeat blood donors - Georgia, 2017-2023.Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine · 2025Article
- Blood Banking Capacity in Low-and Middle-Income Countries: Covid-19 Convalescent Plasma in Context.Current topics in microbiology and immunology · 2025Review
- Evaluation of Knowledge, Attitudes and Practices for Hepatitis B Virus Infection Among Primary Healthcare Physicians in Georgia.Journal of viral hepatitis · 2024Article
- Nationwide Hepatitis C Serosurvey and Progress Towards Hepatitis C Virus Elimination in the Country of Georgia, 2021.The Journal of infectious diseases · 2023Article
- Advancing blood transfusion safety using molecular detection in the country of Georgia.Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine · 2023Article
- Toward reaching hepatitis B goals: hepatitis B epidemiology and the impact of two decades of vaccination, Georgia, 2021.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2023Article
- Hepatitis C care cascade among patients with and without tuberculosis: Nationwide observational cohort study in the country of Georgia, 2015-2020.PLoS medicine · 2023Observational
- Association of Treated and Untreated Chronic Hepatitis C With the Incidence of Active Tuberculosis Disease: A Population-Based Cohort Study.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023Article
- Risk factors and genotype distribution of hepatitis C virus in Georgia: A nationwide population-based survey.PloS one · 2022Article
- Guidance for the procurement of COVID-19 convalescent plasma: differences between high- and low-middle-income countries.Vox sanguinis · 2021Article
- [Exploring the health education model for chronic hepatitis C micro-elimination in Guizhou Province from a global perspectives].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 5 institutions in 2 countries.
Funding
Abstract
backgroundIn April 2015, the government of Georgia (country) initiated the world's first national hepatitis C elimination program. An analysis of blood donor infectious screening data was conducted to inform a strategic plan to advance blood transfusion safety in Georgia. STUDY DESIGN AND
methodsDescriptive analysis of blood donation records (2015-2017) was performed to elucidate differences in demographics, donor type, remuneration status, and seroprevalence for infectious markers (hepatitis C virus antibody [anti-HCV], human immunodeficiency virus [HIV], hepatitis B virus surface antigen [HBsAg], and Treponema pallidum). For regression analysis, final models included all variables associated with the outcome in bivariate analysis (chi-square) with a p value of less than 0.05.
resultsDuring 2015 to 2017, there were 251,428 donations in Georgia, representing 112,093 unique donors; 68.5% were from male donors, and 51.2% of donors were paid or replacement (friends or family of intended recipient). The overall seroprevalence significantly declined from 2015 to 2017 for anti-HCV (2.3%-1.4%), HBsAg (1.5%-1.1%), and T. pallidum (1.1%-0.7%) [p < 0.0001]; the decline was not significant for HIV (0.2%-0.1%). Only 41.0% of anti-HCV seropositive donors underwent additional testing to confirm viremia. Infectious marker seroprevalence varied by age, sex, and geography. In multivariable analysis, first-time and paid donor status were associated with seropositivity for all four infectious markers.
conclusionA decline during the study period in infectious markers suggests improvement in blood safety in Georgia. Areas that need further improvement are donor recruitment, standardization of screening and diagnostic follow-up, quality assurance, and posttransfusion surveillance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.